Wonride MV 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.3mg), designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, reducing postprandial hyperglycemia. The sustained-release formulation ensures a gradual release of active ingredients, promoting better patient compliance and steady glycemic control throughout the day. Wonride MV 1 Tablet SR is indicated for patients inadequately controlled on diet and exercise alone or in combination with other antidiabetic agents. It is essential to monitor blood glucose levels regularly to adjust therapy and minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Caution is advised in patients with renal or hepatic impairment, and it should be used under medical supervision. Lifestyle modifications including diet and exercise remain integral to the effective management of diabetes when using this combination therapy.